Free Cash Flow (Quarterly) Chart

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 -29.97M
March 31, 2026 -33.10M
December 31, 2025 -25.06M
September 30, 2025 -22.53M
June 30, 2025 -26.28M
March 31, 2025 -27.19M
December 31, 2024 -23.27M
September 30, 2024 -22.67M
June 30, 2024 -22.52M
March 31, 2024 -20.65M
December 31, 2023 -15.63M
September 30, 2023 -13.20M
June 30, 2023 -10.50M
March 31, 2023 -12.03M
December 31, 2022 -8.651M
September 30, 2022 -8.166M
June 30, 2022 -9.321M
March 31, 2022 -8.425M
December 31, 2021 -9.403M
September 30, 2021 -8.938M
June 30, 2021 -12.20M
March 31, 2021 -9.597M
December 31, 2020 -12.30M
September 30, 2020 -6.723M
June 30, 2020 -7.772M
Date Value
March 31, 2020 -16.33M
December 31, 2019 -9.956M
September 30, 2019 -11.42M
June 30, 2019 -12.94M
March 31, 2019 -10.96M
December 31, 2018 -10.55M
September 30, 2018 -8.778M
June 30, 2018 -10.40M
March 31, 2018 -9.69M
December 31, 2017 -9.904M
September 30, 2017 -8.25M
June 30, 2017 -7.672M
March 31, 2017 -2.903M
December 31, 2016 -2.19M
September 30, 2016 -2.868M
June 30, 2016 8.013M
March 31, 2016 -11.33M
December 31, 2015 -8.858M
September 30, 2015 -8.283M
June 30, 2015 -8.554M
March 31, 2015 -7.419M
December 31, 2014 -6.025M
September 30, 2014 -5.395M
June 30, 2014 -7.093M
March 31, 2014 -6.279M

Free Cash Flow Definition

Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 3.433B
Insmed, Inc. -95.09M
United Therapeutics Corp. 202.20M
Vertex Pharmaceuticals, Inc. 1.013B
ACADIA Pharmaceuticals, Inc. 95.69M